Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2026Nature Cardiovascular Research

Risk-guided cardioprotection may target therapy to highest-benefit patients and avoid unnecessary treatment.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a risk-guided cardioprotection approach improve cardiovascular outcomes in patients receiving cardiotoxic cancer therapies compared to standard approaches?

Population

Patients receiving potentially cardiotoxic cancer therapies

Comparison

Risk-guided cardioprotection approach vs Standard approach based on cancer type and…

Design

Review

Key result

A risk-guided cardioprotection approach in cardio-oncology may enable the delivery of targeted therapy to patients who derive the greatest cardiovascular benefit, avoiding unnecessary treatment.

Authors

KWKai Yi WuDLDae Hyun LeeIHIvy S. Han

Discussion

Loading...

Member takes

Overview

May inform selective cardioprotection in high-risk patients; leaves open need for randomized validation.

Key Points

  • To evaluate evidence for risk-guided cardioprotection strategies aimed at preventing cardiotoxicity, such as cardiomyopathy and heart failure, during cancer therapy.
  • Reviewed contemporary clinical literature assessing primary cardioprotection strategies across diverse cancer types and antineoplastic regimens.
  • Analyzed recent trials and evolving paradigms in cardio-oncology that evaluate personalized interventions targeting baseline and dynamic cardiovascular risk factors.
  • Unselected cardioprotective trials based solely on cancer diagnosis or therapy regimen showed modest to no significant benefit on subclinical or clinical cardiotoxicity.
  • Cardioprotective interventions stratified by individualized cardiovascular risk optimize therapeutic efficacy by directing treatment to patients with highest vulnerability while sparing low-risk populations.

Structured PICO

Does a risk-guided cardioprotection approach improve cardiovascular outcomes in patients receiving cardiotoxic cancer therapies compared to standard approaches?

P
Population
Patients receiving potentially cardiotoxic cancer therapies
I
Intervention
Risk-guided cardioprotection approach
C
Comparator
Standard approach based on cancer type and treatment regimen regardless of baseline cardiovascular risk
O
Outcome
Attenuation of cardiovascular dysfunction and cardiotoxicity

This review highlights the potential of risk-guided cardioprotection to tailor cardiovascular care in cardio-oncology, moving away from a one-size-fits-all approach.

Cite This Study

Wu et al. (2026) conducted a review in Cancer therapy-induced cardiotoxicity. Risk-guided cardioprotection was evaluated. A risk-guided cardioprotection approach in cardio-oncology may enable the delivery of targeted therapy to patients who derive the greatest cardiovascular benefit, avoiding unnecessary treatment.

synapsesocial.com/papers/6aacf80e0c46fbdff987ddcbhttps://doi.org/10.1038/s44161-026-00869-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardioprotection in oncology: Mechanisms, risks and therapeutic strategies2026
  2. 2Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection2026 · 2 citations
  3. 3An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity2014 · 11 citations
  4. 4Prevention and Treatment of Cardiotoxicity in Cancer Patients2025
  5. 5Oncologic therapies associated with cardiac toxicities: how to minimize the risks2019 · 8 citations